Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial

Roberto Diletti(Erasmus University Rotterdam), Vasim Farooq(Erasmus MC), Chrysafios Girasis(Erasmus MC), Christos V. Bourantas(Erasmus MC), Y. Onuma(Erasmus MC), Jung Ho Heo(Erasmus University Rotterdam), Bill D. Gogas(Erasmus University Rotterdam), Robert‐Jan van Geuns(Erasmus MC), E. Regar(Erasmus University Rotterdam), Bernard De Bruyne(Onze Lieve Vrouwziekenhuis Hospital), Dariusz Dudek(Jagiellonian University), Leif Thuesen(Aarhus University Hospital), Bernard Chevalier(Hôpital Privé Jacques Cartier), Dougal McClean(Christchurch Hospital), Stephan Windecker(University Hospital of Bern), Robert Whitbourn(St Vincent's Hospital Melbourne), Peter Smits(Maasstad Ziekenhuis), J. J. Koolen(Catharina Ziekenhuis), Ian T. Meredith(Monash Medical Centre), Li X(Abbott (United States)), Karine Miquel‐Hébert(Abbott (Belgium)), Susan Veldhof(Abbott (Belgium)), H. M. Garcia-Garcia(Cardialysis (Netherlands)), John A. Ormiston(Auckland City Hospital), P. W. Serruys(Erasmus MC)
Heart
October 31, 2012
Cited by 82Open Access
Full Text

Abstract

BACKGROUND: The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. METHODS: In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and ≥2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. RESULTS: At 2-year angiographic follow-up no differences in late lumen loss (0.29±0.16 mm vs 0.25±0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25±3.47 mm(2) vs 13.09±3.38 mm(2) p=0.0015), scaffold area (5.76±0.96 mm(2) vs 6.41±1.30 mm(2) p=0.0008) and lumen area (5.71±0.98 mm(2) vs 6.20±1.27 mm(2) p=0.0155) between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events (7.3% vs 10.2%, p=0.7335), myocardial infarction (4.9% vs 1.7%, p=0.5662) or ischaemia-driven target lesion revascularisation (2.4% vs 8.5%, p=0.3962) were reported between small and large vessels. No deaths or scaffold thrombosis were observed. CONCLUSIONS: Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels.


Related Papers

No related papers found

Powered by citation graph analysis